



Published in final edited form as:

Pediatr Res. 2022 February ; 91(3): 486–487. doi:10.1038/s41390-021-01803-0.

Prognostic MRS in Neonatal Encephalopathy: Closer to generalizability

Jaylyn Waddell

Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA

In the current issue of *Pediatric Research*, Barta et al.¹ present ¹H MRS data of deep gray matter acquired from infants suffering hypoxic ischemic encephalopathy (HIE) across the first two weeks of life in the manuscript entitled “Predictive performance and metabolite dynamics of proton MR spectroscopy in neonatal hypoxic-ischemic encephalopathy.” Metabolites N-acetyl-aspartate (NAA), creatine (Cr) and myo Inositol (mI) were quantified in the first two weeks of life, and the NAA/Cr and mI/NAA ratios were calculated to determine whether these ratios are useful predictors of outcome at 18–26 months of age. Infants were treated with therapeutic hypothermia. The utility of a reliable predictor of outcome using MRS is high, increasing efficiency of clinical trials, since it is non-invasive and can predict long-term outcomes across a range of post-injury intervals. However, differences in brain region(s) analyzed, gestational age, postnatal age at the time of data acquisition, and technical details surrounding data acquisition have made establishment of a reliable prognostic indicator across studies elusive.

HIE is a multi-phase brain injury characterized by acute and protracted metabolic dysregulation in brain. Acute loss of oxygen and blood flow disrupts mitochondrial function, depleting both ATP and phosphocreatine, reducing supply of phosphates that normally provide metabolic support for basic cellular functions^{2,3}. Loss of blood flow and hypoxia cause the end product of anaerobic metabolism, lactate, to accumulate as it cannot be catabolized or cleared by blood flow⁴. This acute spike in lactate can be quickly cleared during resuscitation and typically resolves to normal levels within hours, but persistently high cerebral lactate can occur over the initial days of life, and is very likely to indicate severe injury and poor outcome⁵. In cases of moderate to severe HIE that involve injury of the basal ganglia or thalamus, local cerebral lactate levels remains elevated for days to weeks^{5,6}. NAA is synthesized from acetyl-CoA in neuronal mitochondria, and in the healthy developing brain, NAA gradually increases (reviewed in^{4,7}). When NAA remains low after developmental brain injury, outcomes are typically poor⁸. The Lac/NAA ratio in a piglet model of HIE was strongly positively correlated with cell death and microglial activation in the basal ganglia and thalamus in the first 48 hours after injury⁹. Whether this ratio remains predictive at later timepoints and in different manifestations of injury (e.g., watershed regions) is unclear, but provides an important insight into the potential mechanistic resolution of MRS and specific metabolite ratios. mI is very high in early

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

655 W. Baltimore St, 13th floor, Baltimore, MD 21201, Phone: 410-406-1473, jwaddell@som.umaryland.edu.

development, decreasing with both gestational and postnatal age^{7,10}. mI is an osmolyte and a precursor for lipid synthesis from inositol, regulating membrane dynamics¹¹. Barta et al.¹ found that both the NAA/Cr and mI/NAA ratios can predict outcomes when data are acquired within the first 14 days of life. In infants that exhibit good outcome, gestational age also contributes to these metabolite ratios, similar to healthy newborn infants, where the NAA/Cr ratio increases, while the mI/NAA ratio decreases as development progresses¹⁰. No such relationship was evident in those facing a poor outcome. Both NAA and Cr are higher in infants born at later gestational ages, but lower than levels observed in the adult¹⁰. The authors conclude that when HIE is less severe, the typical developmental progression of these ratios can be observed, while more severe injury disrupts this developmental progression.

The ratio of NAA/Cr is not always a clear predictor of outcome in HIE¹². Shibasaki et al. did not find prognostic value in the NAA/Cr ratio at early postnatal ages (within the first 96 hours of life) or after the first week of life¹². However, together, Barta et al. and Shibasaki et al. clearly demonstrate that the level of NAA, is a predictive measure^{1,12}. Infants exhibiting favorable outcome either maintain or increase NAA levels during the first 2 weeks of life, and exhibit higher absolute levels almost invariably compared to infants with poor outcomes¹². Similarly, higher NAA/Cr ratios reported by Barta et al. are associated with better outcomes¹. Shibasaki et al. report absolute values of total Cr, and again, infants exhibiting favorable outcomes have higher Cr levels and maintain them across the first two weeks of life or show a small decrease, while infants exhibiting poor outcomes exhibit lower levels, and are more likely to exhibit precipitous drops in Cr levels¹². Poor outcomes anticipated by NAA/Cr ratios are likely due to a drop in NAA, and not an increase in Cr, as infants with poor outcome exhibit drops in both NAA and Cr¹². Dysregulation of mitochondrial function and energy reserve, indicated by NAA and Cr respectively, can yield variable ratios. However, when MRS is performed around 7 days of life, absolute concentration of thalamic NAA accurately predicted adverse outcomes at follow up around 2 years of age in infants exhibiting encephalopathy with near perfect accuracy¹³. Thus, when possible, quantitative measure of NAA is prognostically very powerful.

When absolute concentrations cannot be acquired due to technical issues, factors like gestational age might provide insight into prognosis, as supported by Barta et al.¹. Patterns of metabolites rather than a single metabolite or single metabolite ratio will likely be further refined as the search for prognostic indicators continues, particularly after the acute phase of injury, when lactate is a reliable indicator that metabolism has been disturbed. Barta et al. make this point using conventional proton MRS within the first 96 hours of birth in infants exhibiting indications of HIE¹⁴. In infants with favorable outcome, the mI/NAA ratio was lower, as was the mI/Cr ratio, while NAA/Cr was higher¹⁴. This likely reflects a more normal progression of brain development, characterized by a decrease in mI and increase in NAA in postnatal development. Use of ratios is valuable, and allows inclusion of more data across sites. Consideration of patterns of ratios with attention to observed changes in the healthy brain as well as differences between favorable and poor outcome across reports can inform judgements on prognosis and facilitate clinical trials. Understanding how variables such as gestational age influence metabolite patterns can further hone expectations, as indications of normal development can be age-matched in subpopulations of infants

suffering with HIE. When patterns of ratios or absolute values do not reflect increasing NAA, decreasing lactate and stable Cr, development is likely severely impaired.

Acknowledgments

This commentary was supported by NIH NINDS P01 HD085928 to M.C McKenna, C.F. Bearer and M.M McCarthy and NIH NINDS P01 HD085928-01A15749 to J. Waddell.

References

1. Barta H et al. (2021) Predictive performance and metabolite dynamics of proton MR spectroscopy in neonatal hypoxic-ischemic encephalopathy. *Pediatr. Res* in press.
2. Mikrogeorgiou A, Xu D, Ferriero DM & Vannucci SJ (2019) Assessing Cerebral Metabolism in the Immature Rodent: From Extracts to Real-Time Assessments. *Dev. Neurosci* 40, 463–474.
3. Rackayova V, Cudalbu C, Pouwels PJW & Braissant O (2017) Creatine in the central nervous system: From magnetic resonance spectroscopy to creatine deficiencies. *Anal. Biochem* 529, 144–157. [PubMed: 27840053]
4. Hüppi PS & Lazeyras F (2001) Proton magnetic resonance spectroscopy (1H-MRS) in neonatal brain injury. *Pediatr. Res* 49, 317–319. [PubMed: 11228255]
5. Wu TW et al. (2018) Cerebral lactate concentration in neonatal hypoxic-ischemic encephalopathy: In relation to time, characteristic of injury, and serum lactate concentration. *Front. Neurol* 9, 1–8. [PubMed: 29403429]
6. Hanrahan J et al. (1998) Persistent increases in cerebral lactate concentration after birth asphyxia. *Pediatr. Res* 44, 304–311. [PubMed: 9727705]
7. Kreis R et al. (2002) Brain metabolite composition during early human brain development as measured by quantitative in vivo 1H magnetic resonance spectroscopy. *Magn. Reson. Med* 48, 949–958. [PubMed: 12465103]
8. Cady EB (1996) Metabolite Concentrations and Relaxation in Perinatal Cerebral Hypoxic-Ischemic Injury*. *Neurochem. Res* 21, 1043–1052. [PubMed: 8897467]
9. Pang R et al. (2020) Proton Magnetic Resonance Spectroscopy Lactate/N-Acetylaspartate Within 48 h Predicts Cell Death Following Varied Neuroprotective Interventions in a Piglet Model of Hypoxia–Ischemia With and Without Inflammation-Sensitization. *Front. Neurol* 0, 883.
10. Kreis R, Ernst T & Ross BD (1993) Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. *Magn. Reson. Med. Off. J. Soc. Magn. Reson. Med* 30, 424–437.
11. Di Paolo G & De Camilli P (2006) Phosphoinositides in cell regulation and membrane dynamics. *Nature* 443, 651–657. [PubMed: 17035995]
12. Shibasaki J et al. (2018) Changes in brain metabolite concentrations after neonatal hypoxic-ischemic encephalopathy. *Radiology* 288, 840–848. [PubMed: 29893645]
13. Lally PJ et al. (2019) Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study. *Lancet Neurol.* 18, 35–45. [PubMed: 30447969]
14. Barta H et al. (2018) Prognostic value of early, conventional proton magnetic resonance spectroscopy in cooled asphyxiated infants. *BMC Pediatr.* 18, 1–11. [PubMed: 29301539]